PROM1 and leukemia: First, using the parental CD19+CD133+ SEM cells, we confirmed the enhanced ability of bispecific CAR-iNKT cells to control leukemia and prolong overall survival when compared with each of the monospecific CAR-iNKT cells at the limiting dose of 106 cells (Figure 2A-B).